# US 2022/0031608 A1 · Compositions and methods for the treatment of presbyopia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031608 A1
- Document ID: US20220031608A1
- Status: Published application
- Kind: A1
- Application number: 17/502,066
- Filed: 2021-10-15
- Published: 2022-02-03
- Earliest claimed: 2013-08-28
- Assignees: Lenz Therapeutics, Inc.
- Applicants: Lenz Therapeutics, Inc.
- Inventors: Gerald Horn
- Web page: https://patentgrep.com/patent/US20220031608A1

## CPC

- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 31/439: the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46)
- A61K 31/4409: only substituted in position 4, e.g. isoniazid, iproniazid
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/02: Inorganic compounds
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 47/38: Cellulose; Derivatives thereof
- A61P 27/10: for accommodation disorders, e.g. myopia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides compositions and methods for the treatment of presbyopia. The compositions preferably comprise aceclidine. The compositions optionally contain a surfactant and a viscosity agent.

## Claims

### Claim 1

A method of treating presbyopia comprising administering to a subject in need thereof an ophthalmological composition comprising aceclidine.

### Claim 2 (depends on 1)

The method of claim 1, wherein aceclidine is at a concentration from about 0.25% to about 2.5% w/v, wherein w/v denotes weight by total volume of the composition.

### Claim 3 (depends on 1)

The method of claim 1, wherein aceclidine is at a concentration from about 0.75% to about 2.5% w/v.

### Claim 4

A method of treating presbyopia comprising administering to a subject in need thereof an ophthalmological composition comprising aceclidine and a viscosity agent.

### Claim 5 (depends on 4)

The method of claim 4, wherein aceclidine is at a concentration from about 0.25% to about 2.5% w/v, wherein w/v denotes weight by total volume of the composition.

### Claim 6 (depends on 4)

The method of claim 4, wherein aceclidine is at a concentration from about 0.75% to about 2.5% w/v.

### Claim 7

A method of treating presbyopia comprising administering a composition comprising aceclidine and one or more nonionic surfactants to a subject in need thereof.

### Claim 8 (depends on 7)

The method of claim 7, wherein aceclidine is at a concentration from about 0.25% to about 2.5% w/v, wherein w/v denotes weight by total volume of the composition.

### Claim 9 (depends on 7)

The method of claim 7, wherein aceclidine is at a concentration from about 0.75% to about 2.5% w/v.

### Claim 10

A method of treating low regular astigmatism, low or high irregular astigmatism, keratoconic ectasia, night vision halos/starbursts, night vision reduced contrast, and low myopia, or hyperopia, with or without astigmatism, comprising administering to a subject in need thereof an ophthalmological composition comprising aceclidine.
